In summary, we have found no advantages in diagnosing DTC by the quantitative measurement of TG mRNA in peripheral blood. We consider that an intensive re-evaluation, including a determination of what percentage of TG mRNA derives from thyroid follicular or cancer cells, is necessary with regard to this method before considering the clinical applications.